ADPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adaptive Biotechnologies's Enterprise Value is $948.5 Mil. Adaptive Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-98.9 Mil. Therefore, Adaptive Biotechnologies's EV-to-FCF for today is -9.59.
The historical rank and industry rank for Adaptive Biotechnologies's EV-to-FCF or its related term are showing as below:
During the past 8 years, the highest EV-to-FCF of Adaptive Biotechnologies was 22.27. The lowest was -51.63. And the median was -4.35.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-03-16), Adaptive Biotechnologies's stock price is $7.28. Adaptive Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.090. Therefore, Adaptive Biotechnologies's PE Ratio (TTM) for today is At Loss.
The historical data trend for Adaptive Biotechnologies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
EV-to-FCF | Get a 7-Day Free Trial | -44.86 | -14.64 | -3.51 | -2.77 | -7.61 |
Adaptive Biotechnologies Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EV-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-2.77 | -1.80 | -2.46 | -5.27 | -7.61 |
For the Biotechnology subindustry, Adaptive Biotechnologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's EV-to-FCF falls into.
Adaptive Biotechnologies's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 948.547 | / | -98.876 | |
= | -9.59 |
Adaptive Biotechnologies's current Enterprise Value is $948.5 Mil.
Adaptive Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (NAS:ADPT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adaptive Biotechnologies's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 7.28 | / | -1.090 | |
= | At Loss |
Adaptive Biotechnologies's share price for today is $7.28.
Adaptive Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Adaptive Biotechnologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Chad M Robins | director, officer: CEO and Chairman | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Kyle Piskel | officer: Principal Accounting Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Stacy L Taylor | officer: SVP and General Counsel | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102 |
Tycho Peterson | officer: Chief Financial Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109 |
Sharon Benzeno | officer: Chief Commercial Ofc Imm Med | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Francis Lo | officer: Chief People Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Julie Rubinstein | officer: President | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Susan Bobulsky | officer: SVP, Diagnostics, clonoSEQ | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Nitin Sood | officer: Chief Commercial Officer, MRD | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
R Mark Adams | officer: Chief Operating Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michelle Renee Griffin | director | 19723 NE 65TH LANE, KIRKLAND WA 98033 |
Michael J Pellini | director | 222 DUTTON MILL RD, WILLISTOWN PA 19380 |
Katey Einterz Owen | director | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Harlan S Robins | officer: Chief Scientific Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Peter M Neupert | director | 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005 |
From GuruFocus
By GuruFocus News • 02-12-2025
By GuruFocus News • 11-09-2024
By GuruFocus News • 11-05-2024
By GuruFocus News • 02-04-2025
By Marketwired • 12-08-2024
By GuruFocus News • 11-07-2024
By Marketwired • 01-02-2025
By GuruFocus News • 02-05-2025
By Marketwired • 12-03-2024
By GuruFocus News • 01-07-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.